Shareholding disclosure

Pictet Funds LUX - Biotech

Declared position

3.04%

Threshold

Crossed upwards

Timeline

Published

20.10.2008

Transaction

25.07.2008

Transfer date

25.07.2008

Voting rights breakdown

Voting rights acquired3.04%

Voting rights sold0%

Below threshold0%

Notice details

CategoryGroup of shareholders

ExchangeXSWX

Notification ID

T6768D6523

Beneficial owner

Pictet Funds LUX - Biotech

Declared address

Pictet Funds (LUX)- Biotech, Luxembourg

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Pictet Funds LUX - Biotech

Basilea Pharmaceutica AG, Allschwil20.10.2008T6768D6523

Disclosure summary

Pictet Funds LUX - Biotech disclosed a holding in Basilea Pharmaceutica AG, Allschwil on the acquisition side, published by SIX Exchange Regulation on 20.10.2008, at 3.04% of voting rights. Notice category: Group of shareholders.

Disclosed position

3.04%

Voting rights acquired

Voting rights acquired3.04%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Pictet Funds LUX - Biotech disclosed a holding in Basilea Pharmaceutica AG, Allschwil, published on 20.10.2008.

Publication date20.10.2008

Transaction date25.07.2008

Transfer date25.07.2008

Issuing companyBasilea Pharmaceutica AG, Allschwil

Beneficial ownerPictet Funds LUX - Biotech

Declared addressPictet Funds (LUX)- Biotech, Luxembourg

CategoryGroup of shareholders

Voting rights acquired3.04%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDT6768D6523

Source: SIX Exchange Regulation · Publication date: 20.10.2008

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open